Mucolipidosis II (I Cell Disorder) Market Size, Share, Growth Report 2032

Industry Perspective:

The global mucolipidosis II (I Cell Disorder) market size was evaluated at $12.8 Billion in 2022 and is slated to hit $15.8 Billion by the end of 2030 with a CAGR of nearly 8.8% between 2023 and 2030.

Request Free Sample

The mucolipidosis II (I cell disorder) market report is an indispensable guide on growth factors, challenges, restraints, and opportunities in the global marketspace. The report covers the geographical market along with a comprehensive competitive landscape analysis. It also includes cash flow analysis, profit ratio analysis, market basket analysis, market attractiveness analysis, PESTEL analysis, SWOT analysis, Porter’s five force analysis, and value chain analysis. Additionally, the mucolipidosis II (I cell disorder) industry report explores the investor and stakeholder space to help companies make data-driven decisions.

Mucolipidosis II (I Cell Disorder) Market: Overview

Mucolipidosis II (I cell disorder) is also referred to as I-cell disease and is a unique lysosomal storage ailment occurring due to deficient enzyme N-acetylglucosamine-1-phosphotransferase activity leading to the inability of internalizing enzymes into lysosomes. In addition to this, the disorder is a rare and an inherited one. Moreover, it is also referred to as sialidosis and the condition is segmented as lysosomal storage disorder (LSD). In this disorder, genetic fluctuations interrupt the normal activity of lysosomes in human cells.

Furthermore, the symptoms and physical findings related to mucolipidosis are generally unfolded or disclosed within three to eight months post-birth of a child. The initial symptoms are cornea opacity and eye movement disorders. Reportedly, Mucolipidosis II is a rare disorder and is projected to occur in nearly 1 in 100,000 to 400,000 persons globally.

Key Insights

• As per the analysis shared by our research analyst, the global mucolipidosis II (I cell disorder) market is projected to expand annually at the annual growth rate of around 8.8% over the forecast timespan (2023-2030)
• In terms of revenue, the global mucolipidosis II (I cell disorder) market size was evaluated at nearly $12.8 billion in 2022 and is expected to reach $15.8 billion by 2030.
• The global mucolipidosis II (I cell disorder) market is anticipated to record massive growth over the forecast period owing to favorable government policies and the allocation of funds for research projects for improving medical treatments.
• Based on product, the low growth of the gross & fine motor skills segment is predicted to contribute majorly towards the market growth over the forecast timeline.
• In terms of treatment, the antibiotics segment is projected to account for a major share of the global market in 2023-2030.
• Region-wise, the Asia-Pacific mucolipidosis II (I cell disorder) market is projected to register the highest CAGR during the assessment period.

Mucolipidosis II (I Cell Disorder) Market: Growth Factors

Massive demand for drugs for treating the symptoms of mucolipidosis II to boost the global market trends

Rise in cases of mucolipidosis II (I cell disorder) among the global population will prompt the expansion of the global mucolipidosis II (I cell disorder) market. The escalating need for a slew of drugs for treating the symptoms of mucolipidosis II (I cell disorder) including delays in the growth of gross and fine motor skills along with a surge in initiatives taken by public & private organizations globally for developing new treatment is likely to accelerate the global market growth. Furthermore, the surge in the demand for improved medical therapies for metabolic disorders will proliferate the size of the global market in the years to come.

Furthermore, favorable government policies and allocation of funds for research projects for improving medical treatments will leverage the global market expansion. In addition to this, a prominent rise in the global population requiring effective medical treatment and the development of strong healthcare infrastructure facilities will favorably impact the global Mucolipidosis II (I cell disorder) market.

Mucolipidosis II (I Cell Disorder) Market: Hindrances

Surging therapy prices to impede the global industry trends

Huge treatment costs are predicted to impede the expansion of the mucolipidosis II (I cell disorder) industry across the globe. In addition to this, strict laws pertaining to treatment of the mucolipidosis II (I cell disorder) can further decimate the growth of the global industry.

Mucolipidosis II (I Cell Disorder) Market: Opportunities

Approval of novel drugs by healthcare authorities across the globe to create new growth opportunities for the global market

Approval of new medicines by various governments and a huge focus on research & development activities for finding a cure as well as treating the mucolipidosis II (I cell disorder) will open new growth opportunities for the global mucolipidosis II (I cell disorder) market.

Mucolipidosis II (I Cell Disorder) Market: Challenges

Alterations in government laws to prove as the biggest challenge in the growth of the global industry

Changes in government regulations due to political uncertainty witnessed in various nations can pose a big challenge to the growth of the global Mucolipidosis II (I Cell Disorder) industry.

Mucolipidosis II (I Cell Disorder) Market: Segmentation

The global mucolipidosis II (I cell disorder) market is sectored into symptoms, treatment, end-user, and region.   

In terms of symptoms, the global mucolipidosis II (I cell disorder) market is sectored into deafness, lack of muscle tone (hypotonia), abnormal spine curvature, changing proportion of mental retardation, low growth of gross & fine motor skills, and others segments. Furthermore, the low growth of the gross & fine motor skills segment, which accounted for more than one-fourth of the global market share in 2022, is predicted to retain its domination status even during 2023-2030. The segmental surge in the next eight years can be attributed to the lack of development of gross and fine motor skills witnessed in the children affected due to mucolipidosis II (I cell disorder) after their birth.

Based on the treatment, the global mucolipidosis II (I cell disorder) industry is divided into antibiotics, experimental therapies, hip replacement, physical therapy, and others segments. The antibiotics segment, which dominated the treatment segment in 2022, is predicted to account for a major market share over the forecast timeframe. The growth of the segment in the coming years can be due to the intake of antibiotics in emerging economies for treating mucolipidosis II (I cell disorder).

In terms of end-user, the global mucolipidosis II (I cell disorder) market is sectored into specialty clinics, homecare, hospitals, and others segments.

Recent Breakthroughs

• In the first quarter of 2021, the U.S. FDA provided orphan drug distribution status to two gene therapies referred to as M6P Gene Therapy for Gaucher disorder with an aim of treating the inherited metabolic disorder mucolipidosis. The move is likely to boost the growth of the mucolipidosis II (I cell disorder) industry across the globe.
• In October 2022, Researchers at the University of Michigan in the U.S. located a new gene TMEM251 in a rare disorder referred to as mucolipidosis type II, a lysosomal storage disease, which causes swelling in the heart & abdomens as well as malformation in the bones. Moreover, the disease also causes internal organ edema as well as skeletal dysplasia.

Mucolipidosis II (I Cell Disorder) Market: Report Scope

Mucolipidosis II (I Cell Disorder) Market: Regional Insights 

North American Mucolipidosis II (I Cell Disorder) market to record noteworthy growth over 2023-2030

North America, which accounted for a major revenue share of the global mucolipidosis II (I cell disorder) market in 2022, is anticipated to dominate the regional market growth over the forecast timeline. The regional market surge over 2023-2030 can be due to the presence of strong healthcare infrastructure in the region. Additionally, an increase in the healthcare expenditure made by governments of the U.S. and Canada will contribute lucratively towards the expansion of the market in North America.

Request Free Sample

On the other hand, the mucolipidosis II (I cell disorder) industry in the Asia-Pacific zone is predicted to record the highest gains of 7.5% in the forthcoming years. The regional market expansion over the forecast timespan can be due to a huge patient population base in countries such as India, China, Indonesia, South Korea, Malaysia, and Thailand. Moreover, unmet medical needs in the region will pave the way for regional industry expansion.

Mucolipidosis II (I Cell Disorder) Market: Competitive Space

The global mucolipidosis II (I cell disorder) market profiles key players such as:

• Sun Pharmaceutical Industries Ltd
• Lupin Limited
• Amgen Inc
• Mylan N.V.
• Sanifit
• Teva Pharmaceutical Industries Ltd
• Alkem Labs
• Cipla Inc.
• Hope Pharmaceuticals
• BSN medical
• Zydus Cadila.

The global mucolipidosis II (I cell disorder) market is segmented as follows:

By Symptoms

• Deafness
• Lack of Muscle Tone (Hypotonia)
• Abnormal Spine Curvature
• Changing Proportion of Mental Retardation
• Low Growth of Gross & Fine Motor Skills
• Others

By Treatment

• Antibiotics
• Physical Therapy
•  Hip Replacement
•  Experimental Therapies
•  Others

By End-User

• Hospitals
• Homecare
• Specialty Clinics
• Others

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa